跳转至内容
Merck
CN

主要文件

查看所有文档

B157

BQ-788

≥95%, endothelin-B (ETRB) blocker, solid

别名:

2,6-二甲基哌啶羰基-γ-甲基-亮氨酸-Nin-(甲氧羰基)-D-色氨酸-D-Nle, N-[N-[N-[(2,6-二甲基-1-哌啶基)羰基]-4-甲基-L-亮氨酰]-1-(甲氧基羰基)-D-色氨酰]-D-正亮氨酸 钠盐

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:
C34H50N5NaO7
化学文摘社编号:
156161-89-6
分子量:
663.78
UNSPSC Code:
12352200
PubChem Substance ID:
329773192
NACRES:
NA.32
MDL number:
MFCD00797882
Assay:
≥95%
Form:
solid
Quality level:
200
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

BQ-788, ≥95%, solid

Quality Level

200

assay

≥95%

form

solid

color

white

solubility

acetonitrile: 0.3 mg/mL, DMSO: 1.2 mg/mL, ethanol: 1.2 mg/mL, H2O: slightly soluble

storage temp.

−20°C

SMILES string

[Na+].CCCC[C@@H](NC(=O)[C@@H](Cc1cn(C(=O)OC)c2ccccc12)NC(=O)[C@H](CC(C)(C)C)NC(=O)N3[C@@H](C)CCC[C@H]3C)C([O-])=O

InChI

1S/C34H51N5O7.Na/c1-8-9-16-25(31(42)43)35-29(40)26(18-23-20-38(33(45)46-7)28-17-11-10-15-24(23)28)36-30(41)27(19-34(4,5)6)37-32(44)39-21(2)13-12-14-22(39)3;/h10-11,15,17,20-22,25-27H,8-9,12-14,16,18-19H2,1-7H3,(H,35,40)(H,36,41)(H,37,44)(H,42,43);/q;+1/p-1/t21-,22+,25-,26-,27+;/m1./s1

InChI key

QCVIFBRTTLMEOV-FUKQNADPSA-M

Gene Information

human ... EDNRB(1910)
mouse ... EDNRB(13618)
rat ... EDNRB(50672)

Application

BQ-788 已被用作人气道平滑肌细胞 (HASMC)、子宫间皮细胞 (UtMC) 衍生的血管平滑肌细胞 (VSMC) 以及人脐静脉内皮细胞 (HUVEC) 的选择性内皮缩血管肽 (ETRB) 阻断剂。

Biochem/physiol Actions

选择性ETB内皮素受体拮抗剂。

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
SLCH9288
SLBZ1908
SLBS0689V
SLBM5550V
SLBK3267V

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Emilia Kansanen et al.
Molecular pharmacology, 92(4), 481-490 (2017-08-06)
Nitro-fatty acids are reactive signaling mediators that are formed when unsaturated fatty acids react with nitric oxide or nitric oxide-derived species. Nitro-fatty acids can modify specific signaling pathways via post-translational modifications of Cys residues in key regulatory proteins. One of
Ovidiu Constantin Baltatu et al.
Frontiers in physiology, 3, 103-103 (2012-04-25)
Several clinical studies have investigated the potential benefits of endothelin receptor antagonism in chronic pathologies such as diabetic kidney disease. However, fluid retention and edema have been identified as major side effects of endothelin receptor antagonists. In the present study
Jie Li et al.
Mediators of inflammation, 2013, 656570-656570 (2013-07-19)
Minimally modified low-density lipoprotein (mmLDL) is a risk factor for cardiovascular disease. The present study investigated the effects of mmLDL on the expression of endothelin type A (ET(A)) receptors in coronary arteries. Rat coronary arteries were organ-cultured for 24 h.
查看所有相关文献

全球贸易项目编号

货号GTIN
B157-200UG04061833426203